Genetically mimicked ASGR1 inhibitors had little association with cholelithiasis, adiposity or diabetes (Additional file 1: Supplemental Figure S3), despite an inverse association with HbA1c (Fig. 3). Here, ASGR1 is linked to cholelithiasis.